Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Intangibles: 2010-2025

Historic Intangibles for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $6.9 million.

  • Arrowhead Pharmaceuticals' Intangibles fell 19.87% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 19.87%. This contributed to the annual value of $6.9 million for FY2025, which is 19.87% down from last year.
  • Arrowhead Pharmaceuticals' Intangibles amounted to $6.9 million in FY2025, which was down 19.87% from $8.6 million recorded in FY2024.
  • Arrowhead Pharmaceuticals' Intangibles' 5-year high stood at $13.7 million during FY2021, with a 5-year trough of $6.9 million in FY2025.
  • Its 3-year average for Intangibles is $8.6 million, with a median of $8.6 million in 2024.
  • Data for Arrowhead Pharmaceuticals' Intangibles shows a maximum YoY dropped of 19.87% (in 2025) over the last 5 years.
  • Arrowhead Pharmaceuticals' Intangibles (Yearly) stood at $13.7 million in 2021, then fell by 12.45% to $12.0 million in 2022, then dropped by 14.21% to $10.3 million in 2023, then declined by 16.57% to $8.6 million in 2024, then declined by 19.87% to $6.9 million in 2025.